Founded in 2016, Curigin is a biotechnology company developing AI-based advanced gene therapies for refractory diseases based on its proprietary, world-first dual-target siRNA technology platform.

Conventional RNAi therapies can cause off-target effects that inhibit unintended gene expression during their process and has therapeutic limitations of targeting a single gene have been reported. To overcome these problems, Curigin has developed a new concept ‘the world shortest siRNA’ that targets/suppresses two or more genes simultaneously and eliminates off-target side effects.